Constructive Bio’s 2025 achievements in non-canonical amino acid (ncAA) incorporation include expanded platform capabilities, new partnerships, and recognition from Nature…
Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities,…
Constructive Bio was selected by Nature Biotechnology as a 2025 Editor’s Pick, recognising the company’s synthetic genomics platform and use…
The New York Times covered the creation of Syn57, an E. coli strain with a 57-codon synthetic genome — the…
Constructive Bio has secured an exclusive licence for tRNA display technology, enabling directed integration of non-canonical amino acids (ncAAs) and…
The Sunday Times named Constructive Bio a ‘Biotech One to Watch’ in its 2025 100 Tech Awards, recognising the Cambridge-based…
Constructive Bio CEO Ola Wlodek presented at the Milner Therapeutics Institute seminar series on rewriting genetic codes to expand the…
Engineering the future of biology with revolutionary genome synthesis and expanded genetic code technology.
QUICK LINKS
JOIN OUR NEWSLETTER
© 2026 Constructive Bio. All rights reserved.